JPRN-jRCT2080223552已完成1 期
Phase I Study of Cobimetinib as a Single Agent or in Combination with other Anticancer Agents in Patients with Advanced Solid Tumors
CHUGAI PHARMACEUTICAL CO., LTD0 个研究点目标入组 42 人开始时间: 2017年6月5日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 42
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Advanced or recurrent cancer that is refractory or ineligible to standard therapy or for which no standard therapy exists.
- •- Histologically or cytologically confirmed solid tumor.
- •- ECOG PS of 0 or 1.
- •- Life expectancy >=12 weeks from the date of enrollment.
- •- Major organ function meets all criteria.
排除标准
- •- Unable to take oral drugs or has a gastrointestinal disorder that would affect gastrointestinal drug absorption.
- •- Pregnant or lactating woman.
- •- Current or previous autoimmune disease.
- •- Positive test result for human immunodeficiency virus (HIV) antibody, hepatitis B surface (HBs) antigen, HBs antibody, hepatitis B core (HBc) antibody, or hepatitis C virus (HCV) antibody (eligible if HCV-RNA-negative).
- •- Current or previous clinically significant liver disease.
- •- Current or previous ophthalmologic findings that indicate a risk of retinal detachment, central serous chorioretinopathy, retinal vein occlusion, or macular degeneration.
- •- History of treatment with immune checkpoint inhibitors.
研究者
相似试验
进行中（未招募）
1 期
A Study of Cobimetinib Administered as Single Agent and in Combination with Venetoclax, with or Without Atezolizumab, in Patients with Relapsed and Refractory Multiple MyelomaEUCTR2017-000830-68-SEF. Hoffman-La Roche Ltd.72
进行中（未招募）
1 期
A Study of Cobimetinib Administered as Single Agent and in Combination with Venetoclax, with or Without Atezolizumab, in Patients with Relapsed and Refractory Multiple MyelomaMultiple Myeloma (MM)MedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2017-000830-68-DEF. Hoffman-La Roche Ltd.72
进行中（未招募）
1 期
A Study of Cobimetinib Administered as Single Agent and in Combination with Venetoclax, with or Without Atezolizumab, in Patients with Relapsed and Refractory Multiple MyelomaMultiple Myeloma (MM)MedDRA version: 20.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000054086EUCTR2017-000830-68-ESF. Hoffman-La Roche Ltd.49
进行中（未招募）
1 期
A Study of Cobimetinib Administered as Single Agent and in Combination with Venetoclax, with or Without Atezolizumab, in Patients with Relapsed and Refractory Multiple MyelomaEUCTR2017-000830-68-DKF. Hoffman-La Roche Ltd.72
进行中（未招募）
1 期
A Study of Cobimetinib Administered as Single Agent and in Combination with Venetoclax, with or Without Atezolizumab, in Patients with Relapsed and Refractory Multiple MyelomaMultiple Myeloma (MM)MedDRA version: 20.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2017-000830-68-FRF. Hoffman-La Roche Ltd.49